Compare INBX & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INBX | CDNA |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | 161 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2020 | 2014 |
| Metric | INBX | CDNA |
|---|---|---|
| Price | $72.00 | $20.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 7 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 218.5K | ★ 751.3K |
| Earning Date | 11-14-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | $1,400,000.00 | ★ $357,998,000.00 |
| Revenue This Year | $563.00 | $14.47 |
| Revenue Next Year | N/A | $11.35 |
| P/E Ratio | ★ N/A | $16.47 |
| Revenue Growth | N/A | ★ 14.46 |
| 52 Week Low | $10.81 | $10.96 |
| 52 Week High | $94.57 | $25.55 |
| Indicator | INBX | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 41.77 | 55.38 |
| Support Level | $69.47 | $16.94 |
| Resistance Level | $76.47 | $21.20 |
| Average True Range (ATR) | 4.77 | 1.07 |
| MACD | -0.76 | 0.06 |
| Stochastic Oscillator | 20.55 | 71.21 |
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.